Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ocular surface disease associated with dupilumab treatment for atopic diseases
Canan Aslı Utine, Gavin Li, Penny A. Asbell, et al.
The Ocular Surface (2020) Vol. 19, pp. 151-156
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Expert consensus on the systemic treatment of atopic dermatitis in special populations
David N. Adam, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 6, pp. 1135-1148
Open Access | Times Cited: 54
Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials
Andreas Wollenberg, Lisa A. Beck, Marjolein de Bruin‐Weller, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 3, pp. 453-465
Open Access | Times Cited: 64
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
Masahiro Kamata, Yayoi Tada
JID Innovations (2021) Vol. 1, Iss. 3, pp. 100042-100042
Open Access | Times Cited: 56
Single-cell transcriptional profiling of murine conjunctival immune cells reveals distinct populations expressing homeostatic and regulatory genes
Jehan Alam, Ghasem Yazdanpanah, Rinki Ratnapriya, et al.
Mucosal Immunology (2022) Vol. 15, Iss. 4, pp. 620-628
Open Access | Times Cited: 30
Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives
DeGaulle I. Chigbu, Bisant A. Labib
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 658-658
Open Access | Times Cited: 28
Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease
Silvia Mariel Ferrucci, Luisa Angileri, Simona Tavecchio, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 5, pp. 2587-2592
Closed Access | Times Cited: 21
Neue und zukünftige Therapieansätze in der Behandlung der allergischen Konjunktivitis
Stefan Kassumeh, Barbara Brunner, Siegfried Priglinger, et al.
Deleted Journal (2024) Vol. 121, Iss. 3, pp. 180-186
Closed Access | Times Cited: 4
Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye
Ken Fukuda, Tatsuma Kishimoto, Tamaki Sumi, et al.
Allergology International (2022) Vol. 72, Iss. 2, pp. 234-244
Open Access | Times Cited: 18
Metabolomic and lipidomic alterations in atopic dermatitis patients with dupilumab-associated ocular surface disease.
VijayKumar Patra, Nora Woltsche, Natalie Bordag, et al.
JID Innovations (2025) Vol. 5, Iss. 3, pp. 100361-100361
Open Access
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
Gavin Li, Meghan Berkenstock, Uri Soiberman
American Journal of Ophthalmology Case Reports (2020) Vol. 19, pp. 100848-100848
Open Access | Times Cited: 25
Safety of dupilumab in patients with atopic dermatitis: expert opinion
Wojciech Francuzik, Aikaterina Alexiou, Margitta Worm
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 9, pp. 997-1004
Closed Access | Times Cited: 21
Drug induced cicatrizing conjunctivitis: A case series with review of etiopathogenesis, diagnosis and management
Swati Singh, Pragnya Rao Donthineni, Swapna S. Shanbhag, et al.
The Ocular Surface (2022) Vol. 24, pp. 83-92
Open Access | Times Cited: 16
Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review
Christine Learned, Stephanie R. Cohen, Kaitlynne Cunningham, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 2, pp. 378-382
Closed Access | Times Cited: 9
Current aspects of vernal and atopic keratoconjunctivitis
Elisabeth M. Messmer, Siegfried Priglinger, Stefan Kassumeh
Deleted Journal (2024) Vol. 121, Iss. 3, pp. 173-179
Closed Access | Times Cited: 3
Diagnostic criteria of chronic conjunctivitis: atopic keratoconjunctivitis and vernal keratoconjunctivitis
Andrea Leonardi, Giuseppe Righetti, Giulia Giovannini, et al.
Current Opinion in Allergy and Clinical Immunology (2023) Vol. 23, Iss. 5, pp. 390-396
Closed Access | Times Cited: 8
Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab–Associated Conjunctivitis in Patients with Atopic Dermatitis
VijayKumar Patra, Nora Woltsche, Urban Čerpes, et al.
Ophthalmology Science (2023) Vol. 4, Iss. 1, pp. 100340-100340
Open Access | Times Cited: 7
Clinical trials of antibody drugs in the treatments of atopic dermatitis
Guihao Zhou, Yueyao Huang, Ming Chu
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 5
Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case–Control Study
Paola Marolo, Simone Ribero, Paolo Caselgrandi, et al.
Cornea (2023) Vol. 43, Iss. 2, pp. 221-227
Closed Access | Times Cited: 5
Dupilumab induced ocular surface disease: A prospective case series
Sayali Prakash Pradhan, Salman Naveed Sadiq, Cristián Cartes, et al.
European Journal of Ophthalmology (2023) Vol. 34, Iss. 3, pp. 691-699
Closed Access | Times Cited: 4
Corneal Complications Related to Dupilumab Use
Jenna Tauber, David C. Ritterband, Joann J. Kang
Eye & Contact Lens Science & Clinical Practice (2024)
Closed Access | Times Cited: 1
Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions
Lichen Li, Dean J. Naisbitt, Yonghu Sun, et al.
Clinical & Experimental Allergy (2024) Vol. 54, Iss. 12, pp. 973-983
Open Access | Times Cited: 1
Increased expression of Filaggrin and Claudin‐1 in the ocular surface of patients with atopic dermatitis
Thais Maria Pinheiro Callou, Raquel Leão Orfali, Mírian Nacagami Sotto, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 36, Iss. 2, pp. 247-254
Closed Access | Times Cited: 8
Blépharo-conjonctivites sous dupilumab : recommandations du groupe CEDRE. Dermatite atopique, conjonctivites et dupilumab : quelle prise en charge ?
Serge Doan, Laurent Arnould, C. Febvay, et al.
Journal Français d Ophtalmologie (2022) Vol. 45, Iss. 3, pp. 277-287
Open Access | Times Cited: 5
Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series
Mélanie Hébert, Susan Ruyu Qi, Eunice You, et al.
BMJ Open Ophthalmology (2022) Vol. 7, Iss. 1, pp. e000947-e000947
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top